renascience pharma limited
renascience pharma limited Company Information
Company Number
09420886
Next Accounts
Nov 2025
Industry
Manufacture of basic pharmaceutical products
Shareholders
peter mollison
haziq patel
View AllGroup Structure
View All
Contact
Registered Address
11 george street west, luton, bedfordshire, LU1 2BJ
Website
renasciencepharma.comrenascience pharma limited Estimated Valuation
Pomanda estimates the enterprise value of RENASCIENCE PHARMA LIMITED at £622.1k based on a Turnover of £468.7k and 1.33x industry multiple (adjusted for size and gross margin).
renascience pharma limited Estimated Valuation
Pomanda estimates the enterprise value of RENASCIENCE PHARMA LIMITED at £0 based on an EBITDA of £-69.6k and a 5.35x industry multiple (adjusted for size and gross margin).
renascience pharma limited Estimated Valuation
Pomanda estimates the enterprise value of RENASCIENCE PHARMA LIMITED at £470.2k based on Net Assets of £248.8k and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Renascience Pharma Limited Overview
Renascience Pharma Limited is a live company located in bedfordshire, LU1 2BJ with a Companies House number of 09420886. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in February 2015, it's largest shareholder is peter mollison with a 25% stake. Renascience Pharma Limited is a young, micro sized company, Pomanda has estimated its turnover at £468.7k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Renascience Pharma Limited Health Check
Pomanda's financial health check has awarded Renascience Pharma Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 8 areas for improvement. Company Health Check FAQs
2 Strong
2 Regular
8 Weak
Size
annual sales of £468.7k, make it smaller than the average company (£33.3m)
- Renascience Pharma Limited
£33.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -19%, show it is growing at a slower rate (5.5%)
- Renascience Pharma Limited
5.5% - Industry AVG
Production
with a gross margin of 40.3%, this company has a comparable cost of product (40.3%)
- Renascience Pharma Limited
40.3% - Industry AVG
Profitability
an operating margin of -16% make it less profitable than the average company (8%)
- Renascience Pharma Limited
8% - Industry AVG
Employees
with 2 employees, this is below the industry average (131)
- Renascience Pharma Limited
131 - Industry AVG
Pay Structure
on an average salary of £59.5k, the company has an equivalent pay structure (£59.5k)
- Renascience Pharma Limited
£59.5k - Industry AVG
Efficiency
resulting in sales per employee of £234.3k, this is less efficient (£302.4k)
- Renascience Pharma Limited
£302.4k - Industry AVG
Debtor Days
it gets paid by customers after 83 days, this is later than average (66 days)
- Renascience Pharma Limited
66 days - Industry AVG
Creditor Days
its suppliers are paid after 95 days, this is slower than average (40 days)
- Renascience Pharma Limited
40 days - Industry AVG
Stock Days
it holds stock equivalent to 144 days, this is more than average (98 days)
- Renascience Pharma Limited
98 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 53 weeks, this is more cash available to meet short term requirements (9 weeks)
53 weeks - Renascience Pharma Limited
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 57.5%, this is a higher level of debt than the average (41%)
57.5% - Renascience Pharma Limited
41% - Industry AVG
RENASCIENCE PHARMA LIMITED financials
Renascience Pharma Limited's latest turnover from February 2024 is estimated at £468.7 thousand and the company has net assets of £248.8 thousand. According to their latest financial statements, we estimate that Renascience Pharma Limited has 2 employees and maintains cash reserves of £347.9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 2 | 4 | 4 | ||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 4,913 | 6,750 | 18,094 | 12,876 | 17,994 | 9,614 | 11,357 | 12,252 | 0 |
| Intangible Assets | 1,531 | 3,063 | 0 | 0 | 0 | 0 | 0 | 0 | 13,783 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 6,444 | 9,813 | 18,094 | 12,876 | 17,994 | 9,614 | 11,357 | 12,252 | 13,783 |
| Stock & work in progress | 110,678 | 141,262 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 106,607 | 0 | 117,089 | 151,945 | 128,449 | 66,547 | 79,778 | 127,038 | 100 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 13,396 | 13,396 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 347,858 | 245,050 | 0 | 0 | 0 | 0 | 0 | 0 | 8,941 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 578,539 | 399,708 | 117,089 | 151,945 | 128,449 | 66,547 | 79,778 | 127,038 | 9,041 |
| total assets | 584,983 | 409,521 | 135,183 | 164,821 | 146,443 | 76,161 | 91,135 | 139,290 | 22,824 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 73,640 | 0 | 56,851 | 69,366 | 62,270 | 112,264 | 83,099 | 97,053 | 25,420 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 261,612 | 101,233 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 335,252 | 101,233 | 56,851 | 69,366 | 62,270 | 112,264 | 83,099 | 97,053 | 25,420 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 1,234 | 1,988 | 944 | 916 | 800 | 1,170 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 933 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 933 | 0 | 1,234 | 1,988 | 944 | 916 | 800 | 1,170 | 0 |
| total liabilities | 336,185 | 101,233 | 58,085 | 71,354 | 63,214 | 113,180 | 83,899 | 98,223 | 25,420 |
| net assets | 248,798 | 308,288 | 77,098 | 93,467 | 83,229 | -37,019 | 7,236 | 41,067 | -2,596 |
| total shareholders funds | 248,798 | 308,288 | 77,098 | 93,467 | 83,229 | -37,019 | 7,236 | 41,067 | -2,596 |
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 3,888 | 0 | |||||||
| Amortisation | 1,532 | 1,531 | |||||||
| Tax | |||||||||
| Stock | -30,584 | 141,262 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 106,607 | -103,693 | -34,856 | 23,496 | 61,902 | -13,231 | -47,260 | 126,938 | 100 |
| Creditors | 73,640 | -56,851 | -12,515 | 7,096 | -49,994 | 29,165 | -13,954 | 71,633 | 25,420 |
| Accruals and Deferred Income | 160,379 | 99,999 | -754 | 1,044 | 28 | 116 | -370 | 1,170 | 0 |
| Deferred Taxes & Provisions | 933 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 102,808 | 245,050 | 0 | 0 | 0 | 0 | 0 | -8,941 | 8,941 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 102,808 | 245,050 | 0 | 0 | 0 | 0 | 0 | -8,941 | 8,941 |
renascience pharma limited Credit Report and Business Information
Renascience Pharma Limited Competitor Analysis
Perform a competitor analysis for renascience pharma limited by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in LU1 area or any other competitors across 12 key performance metrics.
renascience pharma limited Ownership
RENASCIENCE PHARMA LIMITED group structure
Renascience Pharma Limited has no subsidiary companies.
Ultimate parent company
RENASCIENCE PHARMA LIMITED
09420886
renascience pharma limited directors
Renascience Pharma Limited currently has 4 directors. The longest serving directors include Ka Che (Feb 2015) and Mr Mobeen Akhtar (Feb 2015).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ka Che | United Kingdom | 44 years | Feb 2015 | - | Director |
| Mr Mobeen Akhtar | England | 43 years | Feb 2015 | - | Director |
| Mr Peter Mollison | United Kingdom | 44 years | Feb 2015 | - | Director |
| Haziq Patel | England | 50 years | Feb 2015 | - | Director |
P&L
February 2024turnover
468.7k
+48%
operating profit
-75.1k
0%
gross margin
40.3%
+2.87%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
February 2024net assets
248.8k
-0.19%
total assets
585k
+0.43%
cash
347.9k
+0.42%
net assets
Total assets minus all liabilities
Similar Companies
renascience pharma limited company details
company number
09420886
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
February 2015
age
9
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
February 2024
previous names
N/A
accountant
-
auditor
-
address
11 george street west, luton, bedfordshire, LU1 2BJ
Bank
-
Legal Advisor
-
renascience pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to renascience pharma limited.
renascience pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for RENASCIENCE PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
renascience pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
